EMA Withdrawn: Zurampic (lesinurad) — Grünenthal GmbH

View source ↗

Summary

Zurampic (lesinurad) has been withdrawn from EU marketing by Grünenthal GmbH after regulatory decision.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperuricemia

Drugs mentioned

• Zurampic (lesinurad)

Snippet

Status: Withdrawn. Therapeutic area: Hyperuricemia. MAH: Grünenthal GmbH. Decision date: 15/06/2017